Email Artikel ini EFEK SAMPING DAN MANAJEMEN OBAT COVID-19 PADA GANGGUAN FUNGSI GINJAL DAN HATI
Abstrak
COVID-19 (coronavirus disease) merupakan penyakit infeksi yang disebabkan oleh virus korona baru yaitu Severe Acute Respiratory Syndrome Coronavirus-2 atau SARS-CoV-2. Paru-paru menjadi organ utama yang terkait dalam COVID-19, namun beberapa organ lain seperti ginjal dan hati juga penting. Sebagian besar obat yang diterima pasien dieksresikan melalui ginjal dan atau mengalami metabolisme di hati. Oleh karena itu, perubahan fungsi ginjal atau hati secara signifikan dapat mempengaruhi konsentrasi obat karena gangguan ekskresi dan metabolisme, sehingga mengakibatkan toksisitas atau mengurangi efikasi. Tujuan penelitian ini adalah untuk menelaah efek samping dan manajemen obat COVID-19 pada pasien dengan berbagai tingkat gangguan ginjal dan hati sehingga dapat menjadi pertimbangan bagi tenaga kesehatan. Pengobatan COVID-19 dalam penelitian ini mengacu pada Protokol Tata Laksana COVID-19 oleh Kementerian Kesehatan Indonesia. Pencarian literatur dilakukan menggunakan google, google scholar, PubMed dan NCBI. Secara menyeluruh, kemampuan metabolisme dan ekskresi obat remdesivir, oseltamivir, favipiravir, azitromisin, levofloxasin, deksametason, dan antikoagulan serta vitamin C yang digunakan pada pasien dengan gangguan fungsi ginjal dan atau gangguan fungsi hati perlu dipertimbangkan. Rekomendasi dosis obat yang digunakan harus memperhatikan derajat gangguan ginjal dan atau hati sebelum dapat diterapkan.
Kata kunci: COVID-19, fungsi ginjal, fungsi hati
Teks Lengkap:
PDFReferensi
Han, Y., & Yang, H. 2020. The Transmission and Diagnosis of 2019 Novel Coronavirus Infection Disease (COVID-19): A Chinese perspective. Journal of Medical Virology.
World Health Organization. 2020. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva: WHO.
Zhang, C., Shi, L., & Wang, F-S. 2020. Liver injury in COVID-19: Management and Challenges. The Lancet Gastroenterology and Hepatology.
Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., Dong, L., et al. 2020. Kidney Impairment is Associated with in-Hospital Death of COVID-19 patients. MedRxiv.
Menteri Kesehatan. 2021. Protokol Tata Laksana Covid-19 Edisi 2. Kementerian Kesehatan Republik Indonesia.
Rahimi, M.M., Elham, J., Behzad, L., Mehdi, F., Rohollah, V., & Saman, F. 2020. Renal and Liver Injury Following The Treatment Of COVID-19 by Remdesivir. Journal of Nephropathology, Vol. 10 (2).
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y. et al. 2020. Remdesivir in Adults With Severe COVID-19: a Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. The Lancet, 395(10236):1569-78.
Zampino, R., Mele, F., Florio, L.L., Bertolino, L., Andini, R., Galdo, M., et al. 2020. Liver Injury in Remdesivir-Treated COVID-19 Patients. Hepatology International. 1-3.
Marra, F., Smolders, E.J., & El-Sherif, O. et al. 2020. Recommendations for Dosing of Repurposed COVID‑19 Medications in Patients with Renal and Hepatic Impairment.
NIH National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [diunduh pada 23 Februari 2021]. Tersedia dari: https://www.covid19treatmentguidelines.nih.gov/
Nunes, L., & Tacio, M.L. 2020. Use of medicines for COVID-19 Treatment in Patients with Loss of Kidney Function: a Narrative Review. Brazilian Journal of Nephrology.
NCBI. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Database Updated 2021 [diunduh pada 14 Februari 2021]. Tersedia dari: https://www.ncbi.nlm.nih.gov/books/NBK547852/
Du, Y.X., & Chen, X.P. 2020. Favipiravir: Pharmacokinetics and Concerns about Clinical Trials For 2019-nCoV Infection. Clinical Pharmacology and Therapeutics.
Li, Wang, X., Wang, R., Hu, Y., Jiang, S., & Lu, X. 2020. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. Drug Design Development Therapy, Vol. 14: 3001-3013.
Preston R. Clinical Trial US109. Pharmacokinetics of Favipiravir in Volunteers with Hepatic Impairment. [diunduh pada 19 Februari 2021]. Tersedia dari: https://clinicaltrials.gov/ct2/show/NCT01419457 [Diakses pada 19 Februari 2021].
Cojutti, P.G., Ramos-Martin, V., Schiavon, I., Rossi, P., Baraldo, M., Hope, W. et al. 2017. Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. Antimicrobial Agents and Chemotherapy, Vol. 61(3).
Ribic, C., & Crowther, M. 2016. Thrombosis and Anticoagulation in The Setting of Renal Or Liver Disease. Hematology American Society of Hematology, (1):188-195.
de Grooth, H.J., Manubulu-Choo, W.P., Zandvliet, A.S., Spoelstra-de Man , A.M.E., Girbes, A.R., Swart, E.L. et al. 2018. Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens. Chest, Vol.153 (6):1368–77.
Peters, E., Antonelli, M., Wittebole, X., Nanchal, R., François, B., Sakr, Y. et al. 2018. A Worldwide Multicentre Evaluation of The Influence Of Deterioration Or Improvement of Acute Kidney Injury on Clinical Outcome in Critically Ill Patients With and Without Sepsis At ICU Admission: Results From The Intensive Care Over Nations Audit. Critical Care, Vol. 22 (1):188.
Aberg, J.A., Lacy, C., Amstrong, L., Goldman, M., & Lance, L.L. Drug Information Handbook 17th Edition, American PharmacistAssociation.
EMA Europe. Summary of Product Characteristics. [diunduh 28 Februari 2021]. Tersedia dari: https://www.ema.europa.eu/en/documents/product-information/tamiflu-epar-product-information_en.pdf
Aursulesei, V., & Costache, I. I. 2019. Anticoagulation In Chronic Kidney Disease: From Guidelines to Clinical Practice. Clinical Cardiology, Vol. 42 (8): 774–782.
Garcia, D.A., Baglin, T.P., Weitz, J.I., & Samama, M.M. 2012. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, Vol. 141(2).
Askari, H., Sanadgol, N., Azarnezhad, A., Tajbakhsh, A., Rafiei, H., Safarpour, A.R. et al. 2021. Kidney Diseases and COVID-19 Infection: Causes and Effect, Supportive Therapeutics-Nutritional Perspectives. Heliyon, Vol. 7(1).
Ashley, C., & Dunleavy, A. 2019. The Renal Drug Handbook: The ultimate Prescribing Guide for Renal Practitioners, 5 ed. New York: CRC Press.
Gilbert, D.N., Chambers, H.F., Eliopoulos, G.M. 2020. The Sanford Guide to Antimicrobial Therapy 2020. Sperryville: Antimicrobial Therapy, Inc.
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C. et al. 2020. Pathological findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. The Lancet Respiratory Medicine.
DOI: https://doi.org/10.24198/farmaka.v19i4.34645
DOI (PDF): https://doi.org/10.24198/farmaka.v19i4.34645.g16839
Refbacks
Sitasi manajer:
Jurnal ini diindeks dalam:
Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Copyright © 2013 Jurnal Farmaka - All Right Reserved